CCR2 scFv Antibody Binding to Block CCL2 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody therapies targeting the CCL2/CCR2 pathway for treating inflammatory diseases and cancer are suboptimal in efficacy, and there is a need for improved specificity and efficacy in blocking the CCR2/CCL2 axis to inhibit inflammatory monocyte migration and polarize tumor-associated macrophages towards a tumor-suppressive M1 phenotype.
Innovation Solution
Development of single-chain variable fragment (scFv) antibodies that specifically bind to the N-terminal or extracellular loop domains of CCR2, inhibiting CCL2 binding and downstream signaling, thereby blocking inflammatory monocyte migration and promoting M1 macrophage polarization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used to target CCL2/CCR2 pathway, then therapeutic coverage is provided, but efficacy is suboptimal
Solution Approach 1:
The patent extracts and utilizes only the essential antigen-binding variable region (scFv) from the complete antibody molecule, discarding the Fc region and other complex structures. This extraction achieves comparable or superior efficacy while simplifying the molecular structure and reducing immunogenicity.
Solution Approach 2:
The patent creates simplified copies (scFv fragments) that retain the essential binding function of full antibodies. These scFv copies can be produced more easily, have reduced immunogenicity, and can be engineered with improved stability and affinity while maintaining therapeutic efficacy.
2Ease of manufacture
If full-length antibodies are administered, then target binding is achieved, but production cost and complexity increase
Solution Approach 1:
The patent extracts only the necessary scFv domain from full-length antibodies, eliminating the need to produce and purify large amounts of complex full-length antibody molecules. This extraction simplifies manufacturing processes while maintaining therapeutic function.
Solution Approach 2:
The scFv fragments can be produced as transient or disposable therapeutic agents that achieve their effect quickly without requiring the stability and complexity of full-length antibodies. They can be synthesized more cheaply and administered at optimized doses.
3Reliability
If CCL2/CCR2 binding is blocked, then monocyte migration is inhibited, but complete blockade may cause off-target effects
Solution Approach 1:
The scFv antibodies are engineered to bind with high specificity to particular epitopes on CCR2, achieving localized precise inhibition. This localized binding quality prevents off-target effects while maintaining potent blockade of the CCL2/CCR2 axis at the intended target site.
Solution Approach 2:
The patent optimizes binding parameters (affinity, specificity, kinetics) of the scFv antibodies to achieve selective blockade of CCL2/CCR2 interactions. By fine-tuning these parameters, the therapy achieves effective monocyte migration inhibition while minimizing off-target effects through precise parameter control.
Data Source
AI summary
Provided herein are single chain variable fragment antibodies that are directed against N-terminal or extracellular loop regions of CCR2. The scFvs can be used alone or in combination to modify macrophage number and migration and to reduce the growth of tumors.